The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
Open accessAbstract
BACKGROUND: Tumor-infiltrating T cells are associated with survival in epithelial ovarian cancer (EOC), but their functional status is poorly understood, especially relative to the different risk categories and histological subtypes of EOC. METHODOLOGY/PRINCIPAL FINDINGS: Tissue microarrays containing high-grade serous, endometrioid, mucinous and clear cell tumors were analyzed immunohistochemically for the presence of lymphocytes, dendritic cells, neutrophils, macrophages, MHC class I and II, and various markers of activation and inflammation. In high-grade serous tumors from optimally debulked patients, positive associations were seen between intraepithelial cells expressing CD3, CD4, CD8, CD45RO, CD25, TIA-1, Granzyme B, FoxP3, CD20, and CD68, as well as expression of MHC class I and II by tumor cells. Disease-specific survival was positively associated with the markers CD8, CD3, FoxP3, TIA-1, CD20, MHC class I and class II. In other histological subtypes, immune infiltrates were less prevalent, and the only markers associated with survival were MHC class II (positive association in endometrioid cases) and myeloperoxidase (negative association in clear cell cases). CONCLUSIONS/SIGNIFICANCE: Host immune responses to EOC vary widely according to histological subtype and the extent of residual disease. TIA-1, FoxP3 and CD20 emerge as new positive prognostic factors in high-grade serous EOC from optimally debulked patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 1×
“Indeed, CD4+ T cells can be skewed toward this so-called Th17 phenotype by exposure to TGF-b in combination with IL-6, IL-1 or IL-23 [107-109].”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 5×
“Tumor-infiltrating CD3+ T cells are strongly associated with favorable prognosis, specifically when CD3+ cells are localized within tumor epithelium [5-9].”
BackgroundResultInfluentialSato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Bingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378 · cited 4×
“These findings have been extended to the CD8+ T cell subset in particular [10-17], suggesting that cytotoxic T lymphocytes (CTLs) play an important role in the antitumor immune response.”
BackgroundResultInfluentialBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25– T cells
R.Walker, M., Kasprowicz, D. J., Gersuk, V. H., Bènard, A., Van Landeghen, M., Buckner, J. H., & Ziegler, S. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19441 · Cited by 1,245
Macrophage polarization in tumour progression
Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M. G., Rimoldi, M., Biswas, S. K., Allavena, P., & Mantovani, A. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.004 · Cited by 1,241 · cited 2×
“The presence of macrophages has been associated with poor prognosis in various human cancers [135,136].”
Backgrounddu Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113
Woo, E. Y., Chu, C., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., & June, C. H. (2001) · PubMed · Cited by 1,108
Transient expression of FOXP3 in human activated nonregulatory CD4 + T cells
Wang, J., Ioan‐Facsinay, A., van der Voort, E. I. H., Huizinga, T. W. J., & Toes, R. E. M. (2007) · European Journal of Immunology · doi:10.1002/eji.200636435 · Cited by 1,011 · cited 1×
“Although FoxP3 is still regarded as the most reliable marker of Tregs in human cancer [82,83], it can also be expressed by epithelial tumor cells [84-86] and in vitro activated CD4+ and CD8+ T cells [87-95].”
BackgroundSalama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., & Iacopetta, B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7229 · Cited by 991
Dannull, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25947 · Cited by 989
Allan, S. E., Crome, S. Q., Crellin, N. K., Passerini, L., Steiner, T. S., Bacchetta, R., Roncarolo, M. G., & Levings, M. K. (2007) · International Immunology · doi:10.1093/intimm/dxm014 · Cited by 872 · cited 1×
“Although FoxP3 is still regarded as the most reliable marker of Tregs in human cancer [82,83], it can also be expressed by epithelial tumor cells [84-86] and in vitro activated CD4+ and CD8+ T cells [87-95].”
BackgroundThe Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer
Schmidt, M., Böhm, D., von Törne, C., Steiner, E., Puhl, A., Pilch, H., Lehr, H.-A., Hengstler, J. G., Kölbl, H., & Gehrmann, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5206 · Cited by 836
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050232 · Cited by 814 · cited 2×
“We chose to first focus on high-grade serous cases, as the other histological subtypes exhibit distinct biological and clinical properties that are potentially confounding [54,55].”
BackgroundSelf-citationGavin, M. A., Torgerson, T. R., Houston, E., deRoos, P., Ho, W. Y., Stray-Pedersen, A., Ocheltree, E. L., Greenberg, P. D., Ochs, H. D., & Rudensky, A. Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509484103 · Cited by 780
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050930 · Cited by 748 · cited 4×
“Under the influence of IL-6 and IL-10, macrophages in EOC can also express B7-H4, which inhibits T cell proliferation [52].”
BackgroundInfluentialTran, D. Q., Ramsey, H., & Shevach, E. M. (2007) · Blood · doi:10.1182/blood-2007-06-094656 · Cited by 743
Human CD25highFoxp3pos regulatory T cells differentiate into IL-17–producing cells
Koenen, H. J. P. M., Smeets, R. L., Vink, P. M., van Rijssen, E., Boots, A. M. H., & Joosten, I. (2008) · Blood · doi:10.1182/blood-2008-01-133967 · Cited by 736
Differentiation and function of Th17 T cells
Stockinger, B., & Veldhoen, M. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.04.005 · Cited by 721
Natural regulatory T cells: mechanisms of suppression
Miyara, M., & Sakaguchi, S. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.01.003 · Cited by 711
Ovarian cancer: Epidemiology, biology, and prognostic factors
Holschneider, C. H., & Berek, J. S. (2000) · Seminars in Surgical Oncology · doi:10.1002/1098-2388(200007/08)19:1<3::aid-ssu2>3.0.co;2-s · Cited by 694
Identification of IL-17-producing FOXP3+regulatory T cells in humans
Voo, K. S., Wang, Y.-H., Santori, F. R., Boggiano, C., Wang, Y.-H., Arima, K., Bover, L., Hanabuchi, S., Khalili, J., Marinova, E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900408106 · Cited by 689
Zou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1339 · Cited by 653
Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer
Al-Shibli, K. I., Donnem, T., Al-Saad, S., Persson, M., Bremnes, R. M., & Busund, L.-T. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0133 · Cited by 614
Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers
Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay, N. E. H., Mosseri, V., Laccourreye, O., Bruneval, P., Fridman, W. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1886 · Cited by 598
Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level
Roncador, G., Brown, P. J., Maestre, L., Hue, S., Martínez-Torrecuadrada, J. L., Ling, K.-L., Pratap, S., Toms, C., Fox, B. C., Cerundolo, V., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200526189 · Cited by 592
Buckanovich, R. J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., Katsaros, D., O'Brien-Jenkins, A., Gimotty, P. A., & Coukos, G. (2008) · Nature Medicine · doi:10.1038/nm1699 · Cited by 546
Wolf, D., Wolf, A. M., Rumpold, H., Fiegl, H., Zeimet, A. G., Muller-Holzner, E., Deibl, M., Gastl, G., Gunsilius, E., & Marth, C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1244 · Cited by 511
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
Edwards, J. C. W., & Cambridge, G. (2006) · Nature Reviews Immunology · doi:10.1038/nri1838 · Cited by 507
Carreras, J., Lopez-Guillermo, A., Fox, B. C., Colomo, L., Martinez, A., Roncador, G., Montserrat, E., Campo, E., & Banham, A. H. (2006) · Blood · doi:10.1182/blood-2006-04-018218 · Cited by 503
Duluc, D., Delneste, Y., Tan, F., Moles, M.-P., Grimaud, L., Lenoir, J., Preisser, L., Anegon, I., Catala, L., Ifrah, N., et al. (2007) · Blood · doi:10.1182/blood-2007-02-072587 · Cited by 491
Coordination of Early Protective Immunity to Viral Infection by Regulatory T Cells
Lund, J. M., Hsing, L., Pham, T. T., & Rudensky, A. Y. (2008) · Science · doi:10.1126/science.1155209 · Cited by 460
Álvaro, T., Lejeune, M., Salvadó, M. T., Bosch, R., García, J. F., Jaén, J., Banham, A. H., Roncador, G., Montalbán, C., & Piris, M. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1869 · Cited by 450
Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans
Morgan, M. E., van Bilsen, J. H. M., Bakker, A. M., Heemskerk, B., Schilham, M. W., Hartgers, F. C., Elferink, B. G., van der Zanden, L., de Vries, R. R. P., Huizinga, T. W. J., et al. (2005) · Human Immunology · doi:10.1016/j.humimm.2004.05.016 · Cited by 418
Ovarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype
Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N. F., Plüddemann, A., Charles, K., Gordon, S., & Balkwill, F. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.5023 · Cited by 411
Leffers, N., Gooden, M. J. M., de Jong, R. A., Hoogeboom, B.-N., ten Hoor, K. A., Hollema, H., Boezen, H. M., van der Zee, A. G. J., Daemen, T., & Nijman, H. W. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0583-5 · Cited by 402
Negus, R. P. M., Stamp, G., Hadley, J., & Balkwill, F. R. (1997) · Europe PMC (PubMed Central) · Cited by 383
Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma
Wei, S., Kryczek, I., Zou, L., Daniel, B., Cheng, P., Mottram, P., Curiel, T., Lange, A., & Zou, W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4043 · Cited by 379
Foxp3 Expression in Pancreatic Carcinoma Cells as a Novel Mechanism of Immune Evasion in Cancer
Hinz, S., Pagerols-Raluy, L., Oberg, H.-H., Ammerpohl, O., Grüssel, S., Sipos, B., Grützmann, R., Pilarsky, C., Ungefroren, H., Saeger, H.-D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3304 · Cited by 352
Transient regulatory T-cells: A state attained by all activated human T-cells
Pillai, V., Ortega, S. B., Wang, C. K., & Karandikar, N. J. (2007) · Clinical Immunology · doi:10.1016/j.clim.2006.10.014 · Cited by 339
Relationship between B7-H4, Regulatory T Cells, and Patient Outcome in Human Ovarian Carcinoma
Kryczek, I., Wei, S., Zhu, G., Myers, L., Mottram, P., Cheng, P., Chen, L., Coukos, G., & Zou, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1866 · Cited by 337
B‐lymphocyte contributions to human autoimmune disease
Yanaba, K., Bouaziz, J., Matsushita, T., Magro, C. M., St.Clair, E. W., & Tedder, T. F. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00646.x · Cited by 326
Primary T Cell Expansion and Differentiation In Vivo Requires Antigen Presentation by B Cells
Crawford, A., MacLeod, M., Schumacher, T., Corlett, L., & Gray, D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3498 · Cited by 313
Constant, S., Schweitzer, N., West, J., Ranney, P., & Bottomly, K. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.8.3734 · Cited by 302
Morse, M. A., Hobeika, A. C., Osada, T., Serra, D., Niedzwiecki, D., Lyerly, H. K., & Clay, T. M. (2008) · Blood · doi:10.1182/blood-2008-01-135319 · Cited by 300
Ayyoub, M., Deknuydt, F., Raimbaud, I., Dousset, C., Leveque, L., Bioley, G., & Valmori, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900621106 · Cited by 293
T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes.
Ron, Y., & Sprent, J. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.9.2848 · Cited by 284
Clarke, B., Tinker, A. V., Lee, C.-H., Subramanian, S., van de Rijn, M., Turbin, D., Kalloger, S., Han, G., Ceballos, K., Cadungog, M. G., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2008.191 · Cited by 280
Self-citationGeneration and regulation of human CD4 + IL-17-producing T cells in ovarian cancer
Miyahara, Y., Odunsi, K., Chen, W., Peng, G., Matsuzaki, J., & Wang, R.-F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710686105 · Cited by 279
Delivering the kiss of death: progress on understanding how perforin works
Pipkin, M. E., & Lieberman, J. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.04.011 · Cited by 263
Expression of CD68 in Non‐Myeloid Cell Types
Gottfried, E., Kunz‐Schughart, L. A., Weber, A., Rehli, M., Peuker, A., Müller, A., Kastenberger, M., Brockhoff, G., Andreesen, R., & Kreutz, M. (2008) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2008.02091.x · Cited by 260
Chetaille, B., Bertucci, F., Finetti, P., Esterni, B., Stamatoullas, A., Picquenot, J. M., Copin, M. C., Morschhauser, F., Casasnovas, O., Petrella, T., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168096 · Cited by 250
Mahnke, K., Schönfeld, K., Fondel, S., Ring, S., Karakhanova, S., Wiedemeyer, K., Bedke, T., Johnson, T. S., Storn, V., Schallenberg, S., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22617 · Cited by 244
Gilks, C. B., Ionescu, D. N., Kalloger, S. E., Köbel, M., Irving, J., Clarke, B., Santos, J., Le, N., Moravan, V., & Swenerton, K. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.01.003 · Cited by 242
Self-citationThe B cell is the initiating antigen-presenting cell in peripheral lymph nodes.
Janeway, C. A., Ron, J., & Katz, M. E. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.4.1051 · Cited by 241
Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential
Barnett, B., Kryczek, I., Cheng, P., Zou, W., & Curiel, T. J. (2005) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2005.00330.x · Cited by 233
Lee, A. M., Clear, A. J., Calaminici, M., Davies, A. J., Jordan, S., MacDougall, F., Matthews, J., Norton, A. J., Gribben, J. G., Lister, T. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4642 · Cited by 220
A Critical Role for B Cells in the Development of Memory CD4 Cells
Linton, P.-J., Harbertson, J., & Bradley, L. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5558 · Cited by 219
Foxp3 expression in human cancer cells
Karanikas, V., Speletas, M., Zamanakou, M., Kalala, F., Loules, G., Kerenidi, T., Barda, A. K., Gourgoulianis, K. I., & Germenis, A. E. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-19 · Cited by 216
CD4+CD25+ Regulatory Lymphocytes Induce Regression of Intestinal Tumors in ApcMin/+ Mice
Erdman, S. E., Sohn, J. J., Rao, V. P., Nambiar, P. R., Ge, Z., Fox, J. G., & Schauer, D. B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3104 · Cited by 211 · cited 1×
“Furthermore, in murine models, FoxP3+ cells can play a positive role in anti-tumor and anti-viral immunity [37,38].”
BackgroundRonchese, F., & Hausmann, B. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.3.679 · Cited by 206
The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice.
Kurt-Jones, E. A., Liano, D., HayGlass, K. A., Benacerraf, B., Sy, M. S., & Abbas, A. K. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.11.3773 · Cited by 192
Expression of Cyclooxygenase 2 Is an Independent Prognostic Factor in Human Ovarian Carcinoma
Denkert, C., Köbel, M., Pest, S., Koch, I., Berger, S., Schwabe, M., Siegert, A., Reles, A., Klosterhalfen, B., & Hauptmann, S. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64912-7 · Cited by 188
Self-citationPrognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma
Tomšová, M., Melichar, B., Sedláková, I., & Šteiner, I. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.10.016 · Cited by 186
The Regulatory T Cell–Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells
Ebert, L. M., Tan, B. S., Browning, J., Svobodova, S., Russell, S. E., Kirkpatrick, N., Gedye, C., Moss, D., Ng, S. P., MacGregor, D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5664 · Cited by 183
Identification and functional characterization of a TIA-1-related nucleolysin.
Kawakami, A., Tian, Q., Duan, X., Streuli, M., Schlossman, S. F., & Anderson, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8681 · Cited by 183
FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease
Kryczek, I., Liu, R., Wang, G., Wu, K., Shu, X., Szeliga, W., Vatan, L., Finlayson, E., Huang, E., Simeone, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3804 · Cited by 179
Is FOXP3 a bona fide marker for human regulatory T cells?
Roncarolo, M., & Gregori, S. (2008) · European Journal of Immunology · doi:10.1002/eji.200838168 · Cited by 174
Loercher, A. E., Nash, M. A., Kavanagh, J. J., Platsoucas, C. D., & Freedman, R. S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.11.6251 · Cited by 173
The impact of T‐cell immunity on ovarian cancer outcomes
Nelson, B. H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00614.x · Cited by 172
Self-citationCoronella, J. A., Spier, C., Welch, M., Trevor, K. T., Stopeck, A. T., Villar, H., & Hersh, E. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.4.1829 · Cited by 171
FOXP3: Not just for regulatory T cells anymore
Ziegler, S. F. (2007) · European Journal of Immunology · doi:10.1002/eji.200636929 · Cited by 170
CD49d provides access to “untouched” human Foxp3+ Treg free of contaminating effector cells
Kleinewietfeld, M., Starke, M., Mitri, D. D., Borsellino, G., Battistini, L., Rötzschke, O., & Falk, K. (2008) · Blood · doi:10.1182/blood-2008-04-150524 · Cited by 166
Powell, D. J., Felipe-Silva, A., Merino, M. J., Ahmadzadeh, M., Allen, T., Levy, C., White, D. E., Mavroukakis, S., Kreitman, R. J., Rosenberg, S. A., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4919 · Cited by 166
NK- and B-Cell Infiltration Correlates With Worse Outcome in Metastatic Ovarian Carcinoma
Dong, H. P., Elstrand, M. B., Holth, A., Silins, I., Berner, A., Trope, C. G., Davidson, B., & Risberg, B. (2006) · American Journal of Clinical Pathology · doi:10.1309/15b6-6dqm-fyym-78cj · Cited by 165
Nzula, S., Going, J. J., & Stott, D. I. (2003) · PubMed · Cited by 159
Hansen, M. H., Nielsen, H., & Ditzel, H. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171460798 · Cited by 158
Transient T cell depletion causes regression of melanoma metastases
Rasku, M. A., Clem, A. L., Telang, S., Taft, B., Gettings, K., Gragg, H., Cramer, D., Lear, S. C., McMasters, K. M., Miller, D. M., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-12 · Cited by 158
Han, L. Y., Fletcher, M. S., Urbauer, D. L., Müeller, P. R., Landen, C. N., Kamat, A. A., Lin, Y. G., Merritt, W. M., Spannuth, W. A., Deavers, M. T., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4433 · Cited by 153
Ahmadzadeh, M., Felipe-Silva, A., Heemskerk, B., Powell, D. J., Wunderlich, J. R., Merino, M. J., & Rosenberg, S. A. (2008) · Blood · doi:10.1182/blood-2008-06-163048 · Cited by 152
Expression of IL-17 mRNA in Ovarian Cancer
Kato, T., Furumoto, H., Ogura, T., Onishi, Y., Irahara, M., Yamano, S., Kamada, M., & Aono, T. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4618 · Cited by 152
de Jong, D., Koster, A., Hagenbeek, A., Raemaekers, J. M. M., Veldhuizen, D., Heisterkamp, S. H., de Boer, J. P., & Glabbeke, M. M. V. (2008) · Haematologica · doi:10.3324/haematol.13574 · Cited by 145
Callahan, M. J., Nagymányoki, Z., Bonome, T., Johnson, M. E., Litkouhi, B., Sullivan, E. H., Hirsch, M. S., Matulonis, U. A., Liu, J. F., Birrer, M. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0479 · Cited by 143
Regulatory T cells in health and disease
Piccirillo, C. A. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.469 · Cited by 133
Cell-surface IL-7 receptor expression facilitates the purification of FOXP3+ regulatory T cells
Banham, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.10.002 · Cited by 133
Mizukami, Y., Kono, K., Kawaguchi, Y., Akaike, H., Kamimura, K., Sugai, H., & Fujii, H. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604149 · Cited by 130
Hillen, F., Baeten, C. I. M., van de Winkel, A., Creytens, D., van der Schaft, D. W. J., Winnepenninckx, V. J. L., & Griffioen, A. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0353-9 · Cited by 126
Shen, H., Whitmire, J. K., Fan, X., Shedlock, D. J., Kaech, S. M., & Ahmed, R. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1443 · Cited by 115
Nedergaard, B. S., Ladekarl, M. B., Nyengaard, J. R., & Nielsen, K. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.08.089 · Cited by 115
Post-transcriptional regulation of proinflammatory proteins
Anderson, P., Phillips, K., Stoecklin, G., & Kedersha, N. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.1103536 · Cited by 114
Raspollini, M. R., Castiglione, F., Degl’Innocenti, D. R., Amunni, G., Villanucci, A., Garbini, F., Baroni, G., & Taddei, G. L. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi112 · Cited by 114
Ayyoub, M., Deknuydt, F., Raimbaud, I., Dousset, C., Leveque, L., Bioley, G., & Valmori, D. (2009) · The Journal of Immunology · Cited by 114
Gene-targeted B-deficient mice reveal a critical role for B cells in the CD4 T cell response
Liu, Y., Wu, Y. P., Ramarathinam, L., Guo, Y., Huszar, D., Trounstine, M. L., & Zhao, M. (1995) · International Immunology · doi:10.1093/intimm/7.8.1353 · Cited by 106
Defective induction of antigen‐reactive proliferating T cells in B cell‐deprived mice
Ron, Y., BAETSELIER, P. D., Gordon, J., Feldman, M., & Segal, S. (1981) · European Journal of Immunology · doi:10.1002/eji.1830111203 · Cited by 105
Ahmadi, M., Emery, D. C., & Morgan, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1060 · Cited by 105
Kusuda, T., Shigemasa, K., Arihiro, K., Fujii, T., Nagai, N., & Ohama, K. (2005) · Oncology Reports · doi:10.3892/or.13.6.1153 · Cited by 101
Álvaro-Naranjo, T., Lejeune, M., Salvadó-Usach, T., Bosch, R., Reverter‐Branchat, G., Jaén, J., & Pons, L. E. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500220654 · Cited by 100
Asano, N., Oshiro, A., Matsuo, K., Kagami, Y., Ishida, F., Suzuki, R., Kinoshita, T., Shimoyama, Y., Tamaru, J., Yoshino, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5342 · Cited by 88
Hansen, M. H., Nielsen, H., & Ditzel, H. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.5.2701 · Cited by 88
Bamias, A., Tsiatas, M. L., Kafantari, E., Liakou, C. G., Rodolakis, A., Voulgaris, Z., Vlachos, G. D., Papageorgiou, T., Tsitsilonis, O., Bamia, C., et al. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.02.029 · Cited by 86
Interferon-γ expression is an independent prognostic factor in ovarian cancer
Marth, C., Fiegl, H., Zeimet, A. G., Müller‐Holzner, E., Deibl, M., Doppler, W., & Daxenbichler, G. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.05.007 · Cited by 85
Shah, C., Allison, K. H., Garcia, R. L., Gray, H. J., Goff, B. A., & Swisher, E. M. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.010 · Cited by 84
IL‐15 acts as a potent inducer of CD4+CD25hi cells expressing FOXP3
Imamichi, H., Sereti, I., & Lane, H. C. (2008) · European Journal of Immunology · doi:10.1002/eji.200737607 · Cited by 82
Kotlán, B., Simsa, P., Teillaud, J., Fridman, W. H., Tóth, J., McKnight, M. E., & Glassy, M. C. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2278 · Cited by 79
Hasselblom, S., Sigurðadóttir, M., Hansson, U. P., Nilsson‐Ehle, H., Ridell, B., & Andersson, P. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06593.x · Cited by 78
Kooi, S., Zhang, H., Patenia, R. S., Edwards, C. L., Platsoucas, C. D., & Freedman, R. S. (1996) · Cellular Immunology · doi:10.1006/cimm.1996.0301 · Cited by 71
Expansion of activated human naïve T-cells precedes effector function
Brenchley, J. M., Douek, D. C., Ambrozak, D. R., Chatterji, M., Betts, M. R., Davis, L. S., & Koup, R. A. (2002) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2002.02015.x · Cited by 71
Powell, D. J., Attia, P., Ghetie, V. F., Schindler, J. D., Vitetta, E. S., & Rosenberg, S. A. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815dc0e8 · Cited by 66
Rolland, P., Deen, S., Scott, I., Durrant, L., & Spendlove, I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2087 · Cited by 63
Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast.
Yakirevich, E., Izhak, O. B., Rennert, G., Kovacs, Z. G., & Resnick, M. B. (1999) · PubMed · Cited by 62
Leveque, L., Deknuydt, F., Bioley, G., Old, L. J., Matsuzaki, J., Odunsi, K. O., Ayyoub, M., & Valmori, D. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318195b59e · Cited by 62
Roles of CD4+CD25high FOXP3+ Tregs in lymphomas and tumors are complex
Ke, X., Wang, J., Li, L., Chen, I.-L., Wang, H., & Yang, X. (2008) · Frontiers in bioscience · doi:10.2741/2986 · Cited by 55
Revisiting the Prognostic Value of Regulatory T Cells in Patients With Cancer
Badoual, C., Hans, S., Fridman, W. H., Brasnu, D. F., Erdman, S. E., & Tartour, É. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0680 · Cited by 48
Loss of IFNγ Receptor Is an Independent Prognostic Factor in Ovarian Cancer
Duncan, T. J., Rolland, P., Deen, S., Scott, I., Liu, D. T. Y., Spendlove, I., & Durrant, L. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2833 · Cited by 48
Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty.
Ozols, R. F. (2000) · PubMed · Cited by 42
Liu, M., Matsumura, N., Mandai, M., Li, K., Yagi, H., Baba, T., Suzuki, A., Hamanishi, J., Fukuhara, K., & Konishi, I. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.187 · Cited by 37
Leffers, N., Lambeck, A. J. A., de Graeff, P., Bijlsma, A. Y., Daemen, T., van der Zee, A. G. J., & Nijman, H. W. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.043 · Cited by 36
Zeimet, A. G., Reimer, D., Wolf, D. G. F., Fiegl, H., Concin, N., Wiedemair, A., Wolf, A. M., Rumpold, H. F., Müller‐Holzner, E., & Marth, C. (2008) · International Journal of Cancer · doi:10.1002/ijc.24214 · Cited by 34
Woo, Y. L., Sterling, J. C., Crawford, R., van der Burg, S. H., Coleman, N., & Stanley, M. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.056200 · Cited by 28
TIA-1 Positive Tumor-Infiltrating Lymphocytes in Nevi and Melanomas
Lyle, S. R., Salhany, K. E., & Elder, D. E. (2000) · Modern Pathology · doi:10.1038/modpathol.3880009 · Cited by 27
Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast.
Tamiolakis, D., Simopoulos, C., Cheva, A., Lambropoulou, M., Kotini, A., Jivannakis, T., & Papadopoulos, N. (2002) · PubMed · Cited by 24
Akahira, J., Konno, R., Ito, K., Okamura, K., & Yaegashi, N. (2004) · International Journal of Clinical Oncology · doi:10.1007/s10147-003-0360-6 · Cited by 23
Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers
Wang, Y., Ylera, F., Boston, M., Kang, S. G., Kutok, J. L., Klein–Szanto, A. J., & Junghans, R. P. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9409-3 · Cited by 22
Class I histocompatibility antigen expression: A prognostic factor for aneuploid ovarian cancers
Moore, D. H., Fowler, W. C., & Olafsson, K. (1990) · Gynecologic Oncology · doi:10.1016/0090-8258(90)90091-x · Cited by 12
Immune Prognostic Factors in Ovarian Cancer: Lessons from Translational Research
Gimotty, P. A., Zhang, L., Alagkiozidis, I., Cadungog, M. G., Adams, S. F., Chu, C., Katsaros, D., & Coukos, G. (2007) · Disease Markers · doi:10.1155/2007/508350 · Cited by 6
Cited by
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
Li, B., Severson, E., Pignon, J.-C., Zhao, H., Li, T., Novak, J., Jiang, P., Shen, H., Aster, J. C., Rodig, S., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1028-7 · Cited by 2,451
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
The tumor microenvironment at a glance
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Metadata
- Authors
- Milne, K., Köbel, M., Kalloger, S. E., Barnes, R. O., Gao, D., Gilks, C. B., Watson, P. H., & Nelson, B. H.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-07-29
- Volume
- 4
- Issue
- 7
- Pages
- e6412
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2019090872
- Cited by
- 446
- References
- 132
- FWCI
- 16.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.